Research and Markets: Novartis Moving Into the Major League in the Respiratory Market.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c20622) has announced the addition of Respiratory Handbook 2005-15: Novartis Moving Into the Major League to their offering. The respiratory market has experienced below average growth in the last five years (CAGR CAGR See: Compound Annual Growth Rate , 10%) reaching $25.5bn in 2004 in the seven major pharmaceutical markets. Future growth will be essentially flat over the next 10 years (CAGR, 0.6%), estimated to reach $27.1bn in 2015. However, based on the current product pipeline, the position of the key players is expected to change dramatically. This report looks at asthma, COPD COPD chronic obstructive pulmonary disease. COPD abbr. chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) and allergic rhinitis indications; corticosteroids Corticosteroids Definition Corticosteroids are group of natural and synthetic analogues of the hormones secreted by the hypothalamic-anterior pituitary-adrenocortical (HPA) axis, more commonly referred to as the pituitary gland. , beta-2 agonists, leukotriene leukotriene /leu·ko·tri·ene/ (-tri´en) any of a group of biologically active compounds derived from arachidonic acid that function as regulators of allergic and inflammatory reactions. modifiers, antimuscarinics and antihistamines Antihistamines Definition Antihistamines are drugs that block the action of histamine (a compound released in allergic inflammatory reactions) at the H1 classes. It provides an overview of the current respiratory market situation, identifying the leading therapies, companies, indications and drug classes. The report analyzes the potential impact of pipeline therapies on the respiratory market, and includes sales forecasts by indication to 2015. The report inlcudes an analysis of the performance of key respiratory players to 2015 - GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) - Pfizer - Boehringer Ingelheim - AstraZeneca - Merck - Schering-Plough - Sanofi-Aventis - Novartis The respiratory market is dominated by seven multinational drug companies, with combined 2004 revenues of $18.7bn representing 73% of total sales. GlaxoSmithKline is the global leader with 2004 sales in excess of $7bn, over $4.5 billion higher than the nearest rival, Merck. The asthma/COPD market is expected to reach $18.1bn by 2015, with sales shifting towards COPD, which will account for 42% of revenues, following the launch of new products. Roughly 50% of asthma/COPD sales will result from products currently in development, largely replacing sales lost through the patent expiries of Advair/Seretide and Singulair. The most significant launches over the next ten years will be GSKs once-daily inhaled corticosteroid/long-acting beta-2 agonist combination "Super Advair", Novartis long-acting, dual-action bronchodilator bronchodilator /bron·cho·di·la·tor/ (-di´la-ter) 1. expanding the lumina of the air passages of the lungs. 2. an agent which causes dilatation of the bronchi. combination product, GSK's novel intranasal corticosteroid corticosteroid /cor·ti·co·ster·oid/ (-ster´oid) any of the steroids elaborated by the adrenal cortex (excluding the sex hormones) or any synthetic equivalents; divided into two major groups, the glucocorticoids and , Allermist and Mercks Singulair/PG-D2 combination product. Examine the success of currently marketed products in terms of their current and forecasted sales to 2015 with this report. Enhance future strategic planning by benchmarking the current and future performance of key players in the respiratory market and predict the future direction of the respiratory market based on the potential of products in the pipeline For more information visit http://www.researchandmarkets.com/reports/c20622 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion